Genetic advances in cystic fibrosis: To screen, to treat or both?

Disability and Rehabilitation

Volumn 20, Issue 6-7, 1998, Pages 202-208

  Super, Maurice ^a,b   Abbott, Janice ^c  

^a ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

Author keywords

Carrier screening; Cascade carrier screening; Cystic fibrosis; Newborn screening; Relevance of advances in treatment

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTICLE; CYSTIC FIBROSIS; GENETIC COUNSELING; HETEROZYGOTE DETECTION; HUMAN; LIFESPAN; NEWBORN SCREENING; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL;

EID: 0031831238     PISSN: 09638288     EISSN: None     Source Type: Journal    
DOI: 10.3109/09638289809166730     Document Type: Article

References (35)

1. Elborn JS, Shale DJ, Britton JR. Cystic fibrosis: current survival and population estimates to year 2000. Thorax 1991; 46: 881-885.
2. Ranasinha C, Assoufi B, Shak S, et al. Efficacy and safety of short-term administration of aerosolised recombinant human Dnase I in adults with stable stage cystic fibrosis. The Lancet 1993; 342: 199-202.
3. Ramsey BW, Astley SJ, Aitken ML, et al. Efficacy and safety of short-term administration of aerosolised recombinant human deoxyribonuclease in patients with cystic fibrosis. American Review of Respiratory Disease 1993; 148: 145-151.
4. Fuchs H, Borowitz DS, Christiansen DH, et al. Effects of aerosolised recombinant human Dnase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The New England Journal of Medicine 1994; 331: 637-642.
5. Heijerman H, Rossem R, Bakker W. Effect of rhDNase on lung function and quality of life in adult cystic fibrosis patients. The Netherlands Journal of Medicine 1995; 46: 293-297.
6. McElvany NG, Naliamia H, Birrier P, et al. Aerosol alpha-1-antitrypsin treatment for cystic fibrosis. Lancet 1991; 337: 392-394.
7. Hammond KB, Abman SH, Sokol RJ, Accuroso FJ. Efficacy of state screening for cystic fibrosis by assay of trypsinogen concentrations. New England Journal of Medicine 1991; 325: 769-774.
8. Abman SH, Reardon MC, Accuroso FJ, Hammond KB, Sokol RJ. Hypoalbuminaemia at diagnosis as a marker for severe respiratory course in infants with cystic fibrosis identified by newborn screening. Journal of Pediatrics 1985; 107: 933-935.
9. Chatfield S, Owen G, Ryley H, et al. Neonatal screening for cystic fibrosis in Wales and the West Midlands: clinical assessment after 5 years screening. Archives of Disease in Childhood 1991; 66: 29-33. (Follow-up in submission for pump priming to the Welsh Office, Clarke A, Bradley D, Goodchild M, 1995.)
10. Robson M, Abbott J, Dodd M, Webb AK, Wallsworth-Bell J. A cost description of an adult cystic fibrosis centre and cost analyses of treatment categories. Thorax 1992; 47: 684-689.
11. Dauphinus RM. A cost analysis of blood-spot screening newborns for cystic fibrosis. Journal of Clinical Immunoassay 1992; 15: 121-125.
12. Super M, Ivinson A, Schwarz MJ, Elles R, Harris R. Clinic experience of prenatal diagnosis of cystic fibrosis using linked DNA probes. Lancet 1987; ii: 782-784.
13. Brock DJH. Prenatal screening for cystic fibrosis: 5 years' experience reviewed. Lancet 1996; 347: 148-150.
14. Kaback MM, Nathan TJ, Greenwald S. Tay-Sachs disease: heterozygote screening and prenatal diagnosis - US experience and world perspective. In: Kaback MM (ed.) Tay-Sachs Disease: Screening and Prevention. New York: Alan Liss, 1977; 13-36.
15. Modell B, Berdoukas V. The Clinical Approach to Thalassaemia. London: Grune & Stratton, 1984; 354-378.
16. Kerem BS, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245: 1073-1080.
17. Super M, Schwarz MJ, Malone G, Roberts T, Howarth A, Dermody G. Active cascade testing for carriers of cystic fibrosis gene. British Medical Journal 1994; 308: 1462-1465.
18. Chueng MC, Goldberg JD, Kan YW. Prenatal diagnosis of sickle cell anaemia and thalassaemia by analysing fetal cells in maternal blood. Nature Genetics 1996; 14: 264-268.
19. Childs B, Gordis L, Kaback MM, Kazazin HH. Tay-Sachs screening: social and psychological impact. American Journal of Human Genetics 1976; 28: 5508.
20. Zeesman S, Clow CL, Cartier L, Scriver CR. A private view of heterozygosity: eight year follow-up on carriers of Tay-Sachs gene detected by high school screening. American Journal of Medical Genetics 1984; 18: 769-778.
21. Bekker H, Modell M, Denniss G, et al. Uptake of cystic fibrosis testing in primary care: supply push or demand pull? British Medical Journal 1993; 306: 1584-1586.
22. Watson EK, Mayall ES, Lamb J, Chapple J, Williamson, R. Psychological and social consequences of community carrier screening programme for cystic fibrosis. Lancet 1992; 340: 217-220.
23. Harris H, Scotcher D, Hartley N, Wallace A, Craufurd D, Harris R. Cystic fibrosis carrier tests in early pregnancy by general practitioners. British Medical Journal 1993; 306: 1580-1583.
24. Mennie ME, Gilfillan A, Compton M, et al. Prenatal screening for cystic fibrosis. Lancet 1992; 340: 214-216.
25. Meidzybrodska Z H, Hall MH, Mollinson J, et al. Antenatal screening for carriers of cystic fibrosis: randomised trial of stepwise v. couple screening. British Medical Journal 1995; 310: 353-357.
26. Livingstone J, Axton RA, Gilfillan A, et al. Antenatal screening for cystic fibrosis: a trial of the couple model. British Medical Journal 1994; 308: 1459-1462.
27. Axworthy D, Brock DJH, Bobrow M, Marteau TM. Psychological impact of population-based carrier testing for cystic fibrosis: 3 year follow-up. Lancet 1996; 347: 1443-1446.
28. Evers-Kiebooms G, Denayer L, Welkenhuysen M, Cassiman JJ, Van den Berge H. A stigmatising effect of the carrier status for cystic fibrosis? Clinical Genetics 1994; 46: 336-343.
29. Bekker H, Denniss G, Modell M, Bobrow M, Marteau T. The impact of population based screening for carriers of cystic fibrosis. Journal of Medical Genetics 1994; 31: 364-368.
30. Mitchell J, Scriver CR, Clow CL, Kaplan F. What young people think and do when the option for cystic fibrosis carrier testing is available. Journal of Medical Genetics 1993; 30: 538-542.
31. Slovic P. Perception of risk. Science 1987; 23: 280-285.
32. Evers-Kiebooms G, Denayer L, Berghe H. A child with cystic fibrosis. Subsequent family planning decisions, reproduction and use of prenatal diagnosis. Clinical Genetics 1990; 37: 207-215.
33. Conway SP, Allenby K, Pond MN. Patient and parental attitudes toward genetic screening and its implications at an adult cystic fibrosis centre. Clinical Genetics 1994; 45: 308-312.
34. Iles S. The loss of early pregnancy. In: Oates M (ed.) Psychological Aspects of Obstetrics and Gynaecology. Baillière's Clinical Obstetrics and Gynaecology 1989; 3: 769-790.
35. Marteau TM. Psychological consequences are unclear. British Medical Journal 1994; 309: 1429-1430.